Stockreport

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint, Inc.  (EYPT) 
Last eyepoint, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF – No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical [Read more]